Safety and efficacy of neoadjuvant disitamab vedotin in combination with pertuzumab with or without toripalimab for HER2-positive breast cancer: An open-label phase II trial.
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Journal of Clinical Oncology
Authors: Lin-Xiaoxi Ma, Benlong Yang, Shanshan Gu, Tianyu Ren, Dandan Gao, Jianmin Fang, Jiong Wu
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410810219